ESCR
MCID: ESP021
MIFTS: 76

Esophageal Cancer (ESCR) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Esophageal Cancer

Aliases & Descriptions for Esophageal Cancer:

Name: Esophageal Cancer 54 38 12 50 66 13 41 14
Esophageal Carcinoma 12 29 52 14 69
Esophageal Squamous Cell Carcinoma 54 56 66
Squamous Cell Carcinoma of Esophagus 56 69
Gastric Cardia Adenocarcinoma 66 69
Esophageal Neoplasms 42 69
Esophagus Cancer 12 50
Escc 56 66
Esophageal Cancer Esophageal Squamous Cell Carcinoma, Susceptibility to, Included 54
Malignant Tumor of the Middle Third of the Esophagus 12
Malignant Neoplasm of Proximal Third of Esophagus 12
Malignant Neoplasm of Middle Third of Oesophagus 12
Malignant Neoplasm of Distal Third of Esophagus 12
Malignant Neoplasm of Lower Third of Oesophagus 12
Malignant Neoplasm of Middle Third of Esophagus 69
Malignant Tumor of Proximal Third of Esophagus 12
Malignant Tumor of Distal Third of Esophagus 12
Esophageal Squamous Cell Carcinoma, Somatic 54
Malignant Neoplasm of Upper Third Esophagus 12
Malignant Tumor of Abdominal Esophagus 12
Esophageal Epidermoid Carcinoma 56
Squamous Cell Esophageal Cancer 52
Malignant Neoplasm of Esophagus 69
Esophageal Carcinoma, Somatic 54
Esophageal Cancer, Somatic 54
Ca Middle Third Oesophagus 12
Aerodigestive Tract Cancer 66
Ca Lower Third Oesophagus 12
Carcinoma of Oesophagus 12
Carcinoma of Esophagus 12
Cancer of Oesophagus 12
Cancer of Esophagus 12
Escr 66

Characteristics:

Orphanet epidemiological data:

56
squamous cell carcinoma of esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Adult; Age of death: adult;

HPO:

32
esophageal cancer:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Esophageal Cancer

OMIM : 54 Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most common cancers worldwide.... (133239) more...

MalaCards based summary : Esophageal Cancer, also known as esophageal carcinoma, is related to tylosis with esophageal cancer and gastric cardia adenocarcinoma, and has symptoms including chest pain, abnormality of the voice and cough. An important gene associated with Esophageal Cancer is TGFBR2 (Transforming Growth Factor Beta Receptor 2), and among its related pathways/superpathways are DNA Damage and DNA Damage Response. The drugs Photodynamic Therapy (& Photofrin) and Photofrin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and testes, and related phenotypes are cellular and immune system

Disease Ontology : 12 A gastrointestinal system cancer that is located in the esophagus.

NIH Rare Diseases : 50 esophageal cancer is a cancer of the esophagus, the hollow tube that carries food and liquids from the throat to the stomach. as the cancer grows, symptoms may include painful or difficult swallowing, weight loss and coughing up blood. the exact cause is usually not known, but both environmental and genetic factors are throught to play a role in the development of this condition. in the united states, risk factors for developing esophageal cancer include smoking, heavy drinking, obesity, and damage from acid reflux. treatments include surgery, radiation, chemotherapy, and laser therapy. some patients may also need nutritional support, since the cancer or treatment may make it hard to swallow. last updated: 1/12/2012

MedlinePlus : 41 the esophagus is a hollow tube that carries food and liquids from your throat to your stomach. early esophageal cancer usually does not cause symptoms. later, you may have symptoms such as painful or difficult swallowing weight loss a hoarse voice or cough that doesn't go away you're at greater risk for getting esophageal cancer if you smoke, drink heavily, or have acid reflux. your risk also goes up as you age your doctor uses imaging tests and a biopsy to diagnose esophageal cancer. treatments include surgery, radiation, and chemotherapy. you might also need nutritional support, since the cancer or treatment may make it hard to swallow. nih: national cancer institute

UniProtKB/Swiss-Prot : 66 Esophageal cancer: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.

Wikipedia : 71 Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Related Diseases for Esophageal Cancer

Diseases related to Esophageal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
id Related Disease Score Top Affiliating Genes
1 tylosis with esophageal cancer 12.4
2 gastric cardia adenocarcinoma 12.3
3 undifferentiated carcinoma of esophagus 11.9
4 carcinoma of esophagus, salivary gland type 11.9
5 esophageal cancer, childhood 11.8
6 mucoepidermoid esophageal carcinoma 11.8
7 adenocarcinoma 11.1
8 esophagitis 11.1
9 esophagus squamous cell carcinoma 11.0
10 esophageal basaloid squamous cell carcinoma 10.8
11 esophagus small cell carcinoma 10.8
12 esophagus verrucous carcinoma 10.8
13 barrett esophagus/esophageal adenocarcinoma 10.8
14 palmoplantar keratoderma, nonepidermolytic 10.8
15 esophagus sarcoma 10.8
16 oro-mandibular-limb hypogenesis syndrome 10.5 CCND1 CDKN2A GSTM1 TP53
17 connective tissue benign neoplasm 10.5 CCND1 CDKN2A GSTM1 TP53
18 brain stem medulloblastoma 10.5 CCND1 CDKN2A TP53
19 ornithinemia 10.5 CCND1 CDKN2A GSTM1 TP53
20 mycobacterium kansasii 10.5 CCND1 GSTM1 TP53
21 hidradenoma 10.5 CCND1 CDKN2A GSTM1 TP53
22 estrogen-receptor positive breast cancer 10.5 CCND1 CDKN2A TP53
23 advanced sleep phase syndrome 10.5 CCND1 CDKN2A TP53
24 clear cell adenofibroma 10.5 CDKN2A TP53
25 extraocular retinoblastoma 10.5 CCND1 CDK4 CDKN2A TP53
26 integumentary system benign neoplasm 10.5 CCND1 CDK4 CDKN2A TP53
27 episodic ataxia 10.5 CCND1 CDK4 CDKN2A
28 post-surgical hypoinsulinemia 10.5 CCND1 CDK4 CDKN2A TP53
29 house allergic alveolitis 10.5 CDK4 CDKN2A TP53
30 maxillary sinus cholesteatoma 10.5 CCND1 CDKN2A TP53
31 ectodermal dysplasia 10.5 CCND1 CDK4 CDKN2A TP53
32 skeletal tuberculosis 10.5 CCND1 CDKN2A
33 thoracic outlet syndrome 10.5 CCND1 CDK4 CDKN2A TP53
34 placenta praevia 10.5 CCND1 CDK4 CDKN2A GSTM1 TP53
35 lacrimal gland adenoid cystic carcinoma 10.5 CDKN2A TP53
36 ossifying fibromyxoid tumor 10.5 CDK4 CDKN2A TP53
37 chronic monocytic leukemia 10.5 CDKN2A DEC1 TP53 TYMP
38 cervical verrucous carcinoma 10.5 CCND1 CDKN2A TP53 TYMP
39 melanoma metastasis 10.5 CCND1 CDK4 CDKN2A TP53
40 spinal muscular atrophy with progressive myoclonic epilepsy 10.5 CCND1 CDKN2A FHIT TP53
41 uterine cervix leukoplakia 10.5 CDKN2A FHIT TP53
42 hepatic flexure cancer 10.4 CCND1 CDKN2A FHIT GSTM1 TP53
43 grade iii astrocytoma 10.4 CCND1 CDK4 CDKN2A TP53
44 facial dermatosis 10.4 CCND1 CDKN2A FHIT TP53
45 interstitial lung disease 10.4 CDK4 CDKN2A TP53
46 cryoglobulinemia 10.4 CDKN2A FHIT TP53
47 testicular cancer 10.4 CCND1 CDKN2A TGFBR2 TP53 TYMP
48 ladd syndrome 10.4 CCND1 CDKN2A GSTM1 TP53 TYMP
49 placental site trophoblastic tumor 10.4 CDKN2A TP53 TYMP
50 statin toxicity 10.4 CCND1 FHIT TP53

Comorbidity relations with Esophageal Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Deficiency Anemia
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Heart Disease
Neutropenia Protein-Energy Malnutrition
Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Cancer:



Diseases related to Esophageal Cancer

Symptoms & Phenotypes for Esophageal Cancer

Symptoms by clinical synopsis from OMIM:

133239

Clinical features from OMIM:

133239

Human phenotypes related to Esophageal Cancer:

56 32 (show all 17)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chest pain 56 32 Frequent (79-30%) HP:0100749
2 abnormality of the voice 56 32 Frequent (79-30%) HP:0001608
3 cough 56 32 Frequent (79-30%) HP:0012735
4 lymphadenopathy 56 32 Occasional (29-5%) HP:0002716
5 nausea and vomiting 56 Frequent (79-30%)
6 obesity 32 HP:0001513
7 dysphagia 32 HP:0002015
8 recurrent singultus 32 HP:0100247
9 gastroesophageal reflux 32 HP:0002020
10 feeding difficulties in infancy 56 Very frequent (99-80%)
11 weight loss 32 HP:0001824
12 abnormality of the neck 32 HP:0000464
13 squamous cell carcinoma 32 HP:0002860
14 abnormality of the intestine 32 HP:0002242
15 clinodactyly of the 5th toe 56 Very frequent (99-80%)
16 esophageal carcinoma 56 Very frequent (99-80%)
17 barrett esophagus 32 HP:0100580

UMLS symptoms related to Esophageal Cancer:


abdominal pain, constipation, coughing, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, snoring, sore throat, vertigo/dizziness, equilibration disorder, gastrointestinal gas

MGI Mouse Phenotypes related to Esophageal Cancer:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.25 ALDH2 CCND1 CDK4 CDKN2A DCC LZTS1
2 immune system MP:0005387 10.17 ALDH2 CCND1 CDK4 CDKN2A DCC FHIT
3 hematopoietic system MP:0005397 10.16 ALDH2 CCND1 CDK4 CDKN2A DCC FHIT
4 endocrine/exocrine gland MP:0005379 10.13 ALDH2 CCND1 CDK4 CDKN2A RHBDF2 TGFBR2
5 neoplasm MP:0002006 10.07 LZTS1 TGFBR2 TP53 WWOX ALDH2 CCND1
6 nervous system MP:0003631 10.06 ALDH2 CCND1 CDK4 CDKN2A DCC LZTS1
7 digestive/alimentary MP:0005381 10.04 CDK4 CDKN2A DCC FHIT TGFBR2 TP53
8 liver/biliary system MP:0005370 9.95 ALDH2 CDK4 CDKN2A RHBDF2 TGFBR2 TP53
9 reproductive system MP:0005389 9.81 WWOX ALDH2 CCND1 CDK4 CDKN2A DLEC1
10 pigmentation MP:0001186 9.73 ALDH2 CDK4 CDKN2A DCC RHBDF2 TP53
11 skeleton MP:0005390 9.61 ALDH2 CCND1 CDKN2A RHBDF2 SPRR3 TGFBR2
12 vision/eye MP:0005391 9.23 ALDH2 CCND1 CDK4 CDKN2A DCC RHBDF2

Drugs & Therapeutics for Esophageal Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Photodynamic Therapy (& Photofrin) 17 PORFIMER SODIUM Sanofi-aventis Approved January, 1996
2
Photofrin 17 PORFIMER SODIUM QLT Approved January 1998

Drugs for Esophageal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 540)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
4
Propranolol Approved, Investigational Phase 4,Phase 3 525-66-6 4946
5
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
6
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
8
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
9
Levoleucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
10
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 180288-69-1 9903
11
Norepinephrine Approved Phase 4 51-41-2 439260
12
Oxymetazoline Approved Phase 4 1491-59-4 4636
13
Phenylephrine Approved Phase 4 59-42-7 6041
14
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
15
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
16
Nicotine Approved Phase 4,Phase 1 54-11-5 942 89594
17
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
18
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
20
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
21
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1 73590-58-6 4594
22
Levobupivacaine Approved Phase 4 27262-47-1 92253
23
Iron Approved Phase 4,Phase 1 7439-89-6 23925
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
28
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
29 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
30 Anticholesteremic Agents Phase 4
31 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Hypolipidemic Agents Phase 4,Phase 1
34 Lipid Regulating Agents Phase 4,Phase 1
35 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Adrenergic Agents Phase 4
37 Adrenergic Antagonists Phase 4
38 Adrenergic beta-Antagonists Phase 4,Phase 3
39 Anti-Arrhythmia Agents Phase 4,Phase 2
40 Antihypertensive Agents Phase 4,Early Phase 1
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Vasodilator Agents Phase 4,Phase 2
43 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
47 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1429)
id Name Status NCT ID Phase
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4
3 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4
4 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
5 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
6 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4
7 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4
8 Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer Completed NCT00911092 Phase 4
9 INEC Study: Immuno-modulating Enteral Nutrition in Cancer Completed NCT00333099 Phase 4
10 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection Completed NCT01416077 Phase 4
11 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
12 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
13 Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Completed NCT02320734 Phase 4
14 The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery Completed NCT02439905 Phase 4
15 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
16 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding Completed NCT00838864 Phase 4
17 Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy Completed NCT00526331 Phase 4
18 The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker Completed NCT02666976 Phase 4
19 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX Recruiting NCT02609425 Phase 4
20 Postoperative Pain Management After Minimally Invasive Esophagectomy Recruiting NCT02042313 Phase 4
21 Radiofrequency in the Treatment of Barrett's Oesophagus Recruiting NCT02558504 Phase 4
22 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4
23 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4
24 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4
25 WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture Active, not recruiting NCT01699542 Phase 4
26 The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease Active, not recruiting NCT02505945 Phase 4
27 The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I Not yet recruiting NCT02845479 Phase 4
28 Different Lugol's Solution Concentration for Image Quality of Esophageal Lesions in Chromoendoscopy With Iodine Staining Not yet recruiting NCT03180970 Phase 4
29 Endoscopy Screening for Esophageal Cancer Terminated NCT00927446 Phase 4
30 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4
31 Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery Terminated NCT00887497 Phase 4
32 Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus Terminated NCT00526786 Phase 4
33 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3
34 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3
35 a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent Unknown status NCT01054274 Phase 3
36 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3
37 Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer Unknown status NCT00686114 Phase 3
38 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3
39 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma Unknown status NCT01034683 Phase 3
40 Esophagectomy: Sweet Versus Ivor-Lewis Unknown status NCT01047111 Phase 3
41 Elective or Prophylactic Nodal Irradiation for Esophageal Cancer Unknown status NCT01551589 Phase 3
42 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3
43 Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches Unknown status NCT01053182 Phase 3
44 Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus Unknown status NCT00987857 Phase 3
45 Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy Unknown status NCT01242124 Phase 2, Phase 3
46 Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial Unknown status NCT00193817 Phase 3
47 The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy Unknown status NCT01361750 Phase 3
48 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3
49 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3
50 A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST) Unknown status NCT00652769 Phase 3

Search NIH Clinical Center for Esophageal Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Esophageal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Esophageal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Esophageal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: esophageal neoplasms

Genetic Tests for Esophageal Cancer

Genetic tests related to Esophageal Cancer:

id Genetic test Affiliating Genes
1 Esophageal Neoplasm 29

Anatomical Context for Esophageal Cancer

MalaCards organs/tissues related to Esophageal Cancer:

39
Lymph Node, Lung, Testes, Endothelial, Colon, Breast, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Esophageal Cancer:

18
The Esophagus

Publications for Esophageal Cancer

Articles related to Esophageal Cancer:

(show top 50) (show all 1549)
id Title Authors Year
1
Esophageal Cancer Diagnosed by Thyroid Scintigraphy. ( 28525453 )
2017
2
Comparative evaluation of target volumes defined by deformable and rigid registration of diagnostic PET/CT to planning CT in primary esophageal cancer. ( 28072693 )
2017
3
Association between ALDH2 Glu487Lys polymorphism and the risk of esophageal cancer. ( 28422823 )
2017
4
Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. ( 28086222 )
2017
5
Effect of SATB1 silencing on the proliferation, invasion and apoptosis of TE-1 esophageal cancer cells. ( 28521398 )
2017
6
Future Directions in Improving Outcomes for Patients with Gastric and Esophageal Cancer. ( 28501093 )
2017
7
Azidothymidine inhibits cell growth and telomerase activity and induces DNA damage in human esophageal cancer. ( 28487971 )
2017
8
Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. ( 28503964 )
2017
9
A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. ( 28498434 )
2017
10
Protective Effect of Dietary Calcium Intake on Esophageal Cancer Risk: A Meta-Analysis of Observational Studies. ( 28524093 )
2017
11
Influence of XRCC4 expression in esophageal cancer cellsA on the response to radiotherapy. ( 27338590 )
2017
12
RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. ( 28533408 )
2017
13
Erratum: Effects of food insecurity on the women esophageal cancer in the Zanjan Province. ( 28508854 )
2017
14
LUGOL'S IODINE CHROMOENDOSCOPY VERSUS NARROW BAND IMAGE ENHANCED ENDOSCOPY FOR THE DETECTION OF ESOPHAGEAL CANCER IN PATIENTS WITH STENOSIS SECONDARY TO CAUSTIC/CORROSIVE AGENT INGESTION. ( 28492712 )
2017
15
Folate intake, serum folate levels and esophageal cancer risk: an overall and dose-response meta-analysis. ( 28060731 )
2017
16
The effects of air pollution on mortality and clinicopathological features of esophageal cancer. ( 28489588 )
2017
17
Genetic polymorphisms in TERT are associated with increased risk of esophageal cancer. ( 28060765 )
2017
18
Postoperative fluid overload is a risk factor for adverse surgical outcome in patients undergoing esophagectomy for esophageal cancer: a retrospective study in 335 patients. ( 28086855 )
2017
19
Esophageal Cancer. ( 28075104 )
2017
20
Metabolic Perturbation and Potential Markers in Patients with Esophageal Cancer. ( 28512469 )
2017
21
Transcatheter arterial embolization for intercostal arterio-esophageal fistula in esophageal cancer. ( 28510809 )
2017
22
Effectiveness of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Computerized Tomography (PET-CT) Scan in Identifying Interval Metastases for Patients with Esophageal Cancer. ( 28058562 )
2017
23
A comparison of the toxicity of mono, bis, tris and tetrakis phosphino silver complexes on SNO esophageal cancer cells. ( 28530542 )
2017
24
Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening. ( 28487611 )
2017
25
Chemoradiotherapy for esophageal cancer before or after surgery: It is not just a matter of time. ( 28527619 )
2017
26
Statin use after esophageal cancer diagnosis and survival: A population based cohort study. ( 28486205 )
2017
27
MMP-10, MMP-7, TIMP-1 and TIMP-2 mRNA expression in esophageal cancer. ( 28510611 )
2017
28
Intermittent pneumatic compression in combination with low-molecular weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery. ( 28054341 )
2017
29
Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma. ( 27680978 )
2017
30
PIM1 gene silencing inhibits proliferation and promotes apoptosis of human esophageal cancer cell line Eca-109. ( 27983525 )
2017
31
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios can Predict Treatment Response to Neoadjuvant Therapy in Esophageal Cancer. ( 28083838 )
2017
32
Long non-coding RNA MEG3 induces cell apoptosis in esophageal cancer through endoplasmic reticulum stress. ( 28405686 )
2017
33
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. ( 28314315 )
2017
34
Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer. ( 28476848 )
2017
35
Esophageal Cancer: What You Should Know. ( 28075111 )
2017
36
Nutrition assessment and its relationship with performance and Glasgow prognostic scores in Vietnamese patients with esophageal cancer. ( 28049261 )
2017
37
AKAP4 mediated tumor malignancy in esophageal cancer. ( 27158351 )
2016
38
Clinical Nomogram for Predicting Survival of Esophageal Cancer Patients after Esophagectomy. ( 27215834 )
2016
39
Safety and feasibility of near-infrared image-guided lymphatic mapping of regional lymph nodes in esophageal cancer. ( 27179838 )
2016
40
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. ( 26475334 )
2016
41
From blood to breath: New horizons for esophageal cancer biomarkers. ( 28028355 )
2016
42
Cytomegalovirus esophagitis developing during chemoradiotherapy for esophageal cancer: two case reports. ( 27655584 )
2016
43
Randomized study of the clinical effects of I8-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. ( 27644137 )
2016
44
A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy: SUVmax is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer. ( 27162651 )
2016
45
Outcome and risk factors assessment for adverse events in advanced esophageal cancer patients after self-expanding metal stents placement. ( 27629280 )
2016
46
Regulation of CXCR4/AKT-signaling-induced cell invasion and tumor metastasis by RhoA, Rac-1, and Cdc42 in human esophageal cancer. ( 26631033 )
2016
47
Lysine-specific demethylase-1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancer. ( 26240060 )
2016
48
Increased MALAT1 expression predicts poor prognosis in esophageal cancer patients. ( 27470544 )
2016
49
Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303. ( 27196482 )
2016
50
MiR-328 suppresses the survival of esophageal cancer cells by targeting PLCE1. ( 26773497 )
2016

Variations for Esophageal Cancer

UniProtKB/Swiss-Prot genetic disease variations for Esophageal Cancer:

66
id Symbol AA change Variation ID SNP ID
1 TGFBR2 p.Glu526Gln VAR_015816 rs121918714

ClinVar genetic disease variations for Esophageal Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 LZTS1 NM_021020.3(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh37 Chromosome 8, 20112608: 20112608
2 LZTS1 NM_021020.3(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh37 Chromosome 8, 20111087: 20111087
3 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh37 Chromosome 16, 78466465: 78466465
4 RNF6 NM_005977.3(RNF6): c.305G> A (p.Arg102Lys) single nucleotide variant Pathogenic rs121434522 GRCh37 Chromosome 13, 26789714: 26789714
5 RNF6 NM_005977.3(RNF6): c.724G> A (p.Ala242Thr) single nucleotide variant Pathogenic rs121434523 GRCh37 Chromosome 13, 26789295: 26789295
6 RNF6 NM_005977.3(RNF6): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic rs121434524 GRCh37 Chromosome 13, 26789288: 26789288
7 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic/Likely pathogenic rs28934578 GRCh37 Chromosome 17, 7578406: 7578406
8 TGFBR2 NM_003242.5(TGFBR2): c.1576G> C (p.Glu526Gln) single nucleotide variant Pathogenic rs121918714 GRCh37 Chromosome 3, 30732963: 30732963
9 DCC NM_005215.3(DCC): c.503T> C (p.Met168Thr) single nucleotide variant Pathogenic rs121912967 GRCh37 Chromosome 18, 50432504: 50432504

Cosmic variations for Esophageal Cancer:

9 (show top 50) (show all 7578)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM5049514 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.838+2T>A p.? 23
2 COSM2765083 ZNF831 oesophagus,NS,carcinoma,squamous cell carcinoma c.605T>C p.L202P 23
3 COSM5048967 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.768C>G p.Y256* 23
4 COSM5046823 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.37C>A p.H13N 23
5 COSM5047812 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.668C>G p.S223* 23
6 COSM5047907 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.777C>A p.Y259* 23
7 COSM4834899 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.170C>G p.S57* 23
8 COSM5047811 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.938C>G p.S313C 23
9 COSM5046772 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.80G>C p.C27S 23
10 COSM2158206 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 23
11 COSM5047556 ZNF230 oesophagus,NS,carcinoma,squamous cell carcinoma c.87G>C p.Q29H 23
12 COSM5047304 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1162C>T p.R388W 23
13 COSM5049372 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.71A>T p.E24V 23
14 COSM4546868 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.4099G>A p.D1367N 23
15 COSM5047474 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.10574C>T p.S3525F 23
16 COSM389658 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6845G>A p.R2282Q 23
17 COSM5048642 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.439G>T p.E147* 23
18 COSM5048233 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6266C>A p.P2089H 23
19 COSM2876375 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.8374G>A p.G2792R 23
20 COSM5048796 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.2120C>G p.S707C 23
21 COSM5048093 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9060G>T p.L3020F 23
22 COSM751681 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9517C>T p.P3173S 23
23 COSM5049149 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.4628G>T p.R1543L 23
24 COSM3276999 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.359G>A p.G120E 23
25 COSM5049692 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.3497C>T p.P1166L 23
26 COSM5048958 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.4132C>T p.Q1378* 23
27 COSM5049693 ZFHX3 oesophagus,NS,carcinoma,squamous cell carcinoma c.3496C>T p.P1166S 23
28 COSM127037 ZFAT oesophagus,NS,carcinoma,squamous cell carcinoma c.143C>G p.S48* 23
29 COSM5048211 ZFAT oesophagus,NS,carcinoma,squamous cell carcinoma c.2249G>A p.R750H 23
30 COSM5047133 ZC3H7B oesophagus,NS,carcinoma,squamous cell carcinoma c.476T>A p.L159Q 23
31 COSM5047865 ZC3H6 oesophagus,NS,carcinoma,squamous cell carcinoma c.637T>G p.F213V 23
32 COSM2250480 ZC3H14 oesophagus,NS,carcinoma,squamous cell carcinoma c.1793T>A p.L598* 23
33 COSM3481930 ZC3H11A oesophagus,NS,carcinoma,squamous cell carcinoma c.800C>T p.S267F 23
34 COSM2134440 YME1L1 oesophagus,NS,carcinoma,squamous cell carcinoma c.43C>T p.P15S 23
35 COSM5049679 YME1L1 oesophagus,NS,carcinoma,squamous cell carcinoma c.863-2A>G p.? 23
36 COSM5046790 XPO5 oesophagus,NS,carcinoma,squamous cell carcinoma c.2092T>C p.Y698H 23
37 COSM5047544 XIRP2 oesophagus,NS,carcinoma,squamous cell carcinoma c.5215G>A p.E1739K 23
38 COSM5047950 XIRP2 oesophagus,NS,carcinoma,squamous cell carcinoma c.4627G>C p.E1543Q 23
39 COSM5047255 WWC3 oesophagus,NS,carcinoma,squamous cell carcinoma c.2836C>T p.R946* 23
40 COSM5047360 WRN oesophagus,NS,carcinoma,squamous cell carcinoma c.1475C>T p.S492F 23
41 COSM5048456 WEE1 oesophagus,NS,carcinoma,squamous cell carcinoma c.1212G>T p.K404N 23
42 COSM5049604 WDR66 oesophagus,NS,carcinoma,squamous cell carcinoma c.1475A>T p.K492M 23
43 COSM5047589 WDR64 oesophagus,NS,carcinoma,squamous cell carcinoma c.94G>C p.E32Q 23
44 COSM5049378 VSIG8 oesophagus,NS,carcinoma,squamous cell carcinoma c.331A>G p.I111V 23
45 COSM5048194 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.11390G>A p.R3797Q 23
46 COSM5048630 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.12893T>C p.I4298T 23
47 COSM3369233 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.8197+1G>A p.? 23
48 COSM5047981 VPS13D oesophagus,NS,carcinoma,squamous cell carcinoma c.12795-1G>A p.? 23
49 COSM5049254 VPS13B oesophagus,NS,carcinoma,squamous cell carcinoma c.766C>A p.H256N 23
50 COSM5047579 VPS13B oesophagus,NS,carcinoma,squamous cell carcinoma c.10573G>C p.E3525Q 23

Copy number variations for Esophageal Cancer from CNVD:

7 (show top 50) (show all 64)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32702 1 39027237 40780163 Amplification MYCL1 Esophageal cancer
2 35731 1 66691991 71187083 Deletion CTH Esophageal cancer
3 38511 10 10309026 19155158 Deletion Esophageal cancer
4 41416 10 17811791 65388337 Amplification Esophageal cancer
5 43899 10 50393324 70694787 Deletion Esophageal cancer
6 48565 11 100815801 103042620 Amplification BIRC2 Esophageal cancer
7 48566 11 100815801 103042620 Amplification BIRC3 Esophageal cancer
8 48567 11 100815801 103042620 Amplification YAP1 Esophageal cancer
9 55251 11 50256798 61426521 Deletion Esophageal cancer
10 58612 11 68753086 69985447 Amplification CCND1 Esophageal cancer
11 58613 11 68753086 69985447 Amplification CTTN Esophageal cancer
12 58614 11 68753086 69985447 Amplification FGF19 Esophageal cancer
13 58615 11 68753086 69985447 Amplification FGF3 Esophageal cancer
14 58616 11 68753086 69985447 Amplification FGF4 Esophageal cancer
15 58617 11 68753086 69985447 Amplification MYEOV Esophageal cancer
16 58701 11 69200000 70700000 Gain PPFIA1 Esophageal cancer
17 61418 12 1 132078379 Deletion Esophageal cancer
18 79288 13 68772537 113042980 Deletion Esophageal cancer
19 80978 14 1 105311216 Deletion Esophageal cancer
20 83027 14 19100000 23600000 Gain NFATC4 Esophageal cancer
21 84103 14 23600000 31800000 Gain ARHGAP5 Esophageal cancer
22 84107 14 23600000 36900000 Gain PAX9 Esophageal cancer
23 85295 14 42828345 44176016 Deletion Esophageal cancer
24 111151 17 35097918 35138441 Copy number ERBB2 Esophageal cancer
25 119155 18 1 1118244 Amplification TYMS Esophageal cancer
26 119156 18 1 1118244 Amplification YES1 Esophageal cancer
27 121678 18 46081464 51919972 Deletion SMAD4 Esophageal cancer
28 137284 2 141590067 141951947 Deletion LRP1B Esophageal cancer
29 151504 20 22140447 26145930 Amplification PYGB Esophageal cancer
30 157032 21 1 29932926 Deletion Esophageal cancer
31 160899 22 16558724 17937900 Amplification BID Esophageal cancer
32 160900 22 16558724 17937900 Amplification CLDN5 Esophageal cancer
33 161388 22 18577713 20667607 Amplification CRKL Esophageal cancer
34 161389 22 18577713 20667607 Amplification MAPK1 Esophageal cancer
35 163870 22 31889314 32003182 Amplification LARGE Esophageal cancer
36 166067 3 1 199344050 Deletion Esophageal cancer
37 169829 3 14700000 43600000 Loss RAB5A Esophageal cancer
38 171482 3 168801287 168851758 Amplification EVI1 Esophageal cancer
39 171491 3 168867391 169381563 Amplification MDS1 Esophageal cancer
40 173071 3 189400000 193800000 Gain TP63 Esophageal cancer
41 174749 3 32100000 54400000 Loss SCN10A Esophageal cancer
42 175197 3 3800000 87200000 Loss ATXN7 Esophageal cancer
43 175734 3 43600000 51400000 Loss CTDSPL Esophageal cancer
44 177631 3 59735036 61237133 Deletion FHIT Esophageal cancer
45 179189 3 8700000 14700000 Loss RAF1 Esophageal cancer
46 179592 3 95917505 101945216 Amplification MINA Esophageal cancer
47 190878 4 91972774 162358674 Deletion CASP6 Esophageal cancer
48 190879 4 91972774 162358674 Deletion SMAD1 Esophageal cancer
49 191757 5 10051329 11800765 Amplification CTNND2 Esophageal cancer
50 198525 5 25700000 76400000 Loss F2R Esophageal cancer

Expression for Esophageal Cancer

Search GEO for disease gene expression data for Esophageal Cancer.

Pathways for Esophageal Cancer

Pathways related to Esophageal Cancer according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1 12.32 CCND1 CDK4 CDKN2A TP53 WWOX
2
Show member pathways
12.26 CCND1 CDK4 CDKN2A TP53
3 12.25 CCND1 CDK4 CDKN2A TP53
4
Show member pathways
12.24 CCND1 DCC TGFBR2 TP53
5
Show member pathways
12.23 CCND1 CDK4 CDKN2A TP53
6 12.23 CCND1 CDK4 CDKN2A DCC TGFBR2 TP53
7 12.16 CCND1 CDK4 CDKN2A TP53
8 12.13 CCND1 CDK4 CDKN2A TGFBR2 TP53
9
Show member pathways
12.09 CCND1 CDK4 CDKN2A TGFBR2
10 12.04 CCND1 DCC TGFBR2 TP53
11 12 CCND1 CDK4 TGFBR2 TP53
12 11.91 CCND1 CDK4 CDKN2A TP53
13 11.78 CCND1 CDK4 TGFBR2
14 11.73 CCND1 CDK4 TP53
15 11.71 CCND1 CDK4 CDKN2A TP53
16 11.61 CDKN2A GSTM1 TP53
17
Show member pathways
11.5 CCND1 CDK4 CDKN2A TGFBR2 TP53
18 11.48 CCND1 CDK4 FHIT TP53
19 11.42 CCND1 CDKN2A TP53
20 11.31 CCND1 CDK4 TP53
21 11.11 CCND1 CDK4 TP53
22 11.09 CDK4 CDKN2A TP53
23 10.88 CCND1 CDK4 CDKN2A TP53 TYMP

GO Terms for Esophageal Cancer

Biological processes related to Esophageal Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.73 CDKN2A DCC FHIT TGFBR2 TP53 WWOX
2 negative regulation of cell proliferation GO:0008285 9.72 CDKN2A DEC1 DLEC1 TGFBR2 TP53
3 G1/S transition of mitotic cell cycle GO:0000082 9.63 CCND1 CDK4 CDKN2A
4 cell cycle GO:0007049 9.63 CCND1 CDK4 CDKN2A LZTS1 TMPRSS11A TP53
5 response to organic substance GO:0010033 9.61 CCND1 CDK4 TGFBR2
6 replicative senescence GO:0090399 9.4 CDKN2A TP53
7 mitotic G1 DNA damage checkpoint GO:0031571 9.37 CCND1 TP53
8 animal organ regeneration GO:0031100 9.13 CCND1 CDK4 TGFBR2
9 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 8.8 FHIT TP53 WWOX

Molecular functions related to Esophageal Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 8.62 CCND1 CDK4

Sources for Esophageal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....